Q1 2024 Omeros Corp Earnings Call Transcript
Key Points
- Omeros Corp (OMER) has a strong cash position with $230.3 million available to support ongoing operations and debt service, expected to fund operations into 2026.
- The company is optimistic about the approval of narsoplimab, with strong support from the transplant community and ongoing supply under the expanded access program.
- OMS906, targeting the alternative pathway of complement, is advancing well with multiple ongoing Phase 2 studies showing promising results.
- OMS1029 has successfully completed a Phase 1 study, supporting once quarterly dosing, and is moving towards Phase 2 trials in potential large-value indications like wet AMD.
- Omeros Corp (OMER) is developing OMS527, a PDE7 inhibitor, as a potential treatment for cocaine use disorder with funding from the National Institute on Drug Abuse.
- Omeros Corp (OMER) reported a significant net loss of $37.2 million for the first quarter of 2024, compared to a net loss of $9.1 million in the previous quarter.
- The financial burden of the expanded access program for narsoplimab is being assessed, indicating potential challenges in maintaining the program.
- There is no firm date for the BLA resubmission or the related decision date for approval of narsoplimab, creating uncertainty about the timeline for potential market entry.
- The company faces ongoing challenges with regulatory interactions, as indicated by the lack of detailed updates on progress with the FDA regarding narsoplimab.
- Despite the potential of OMS906, the drug is still in the Phase 2 trial stage, and its success in Phase 3 trials and subsequent market acceptance remains uncertain.
Good afternoon and welcome to today's earnings call for Omeros Corporation. (Operator Instructions) Please be advised that this call is being recorded at the company's request, and a replay will be available on the company's website for one week from today.
I'll now turn the call over to Jennifer Williams, Investor Relations for Omeros.
Good afternoon and thank you for joining the call today. I'd like to remind you that some of the statements that will be made on the call today will be forward-looking statements. These statements are based on management's beliefs and expectations as of today only and are subject to change. All forward-looking statements involve risks and uncertainties that could cause the company's actual results to differ materially. Please refer to the special note regarding forward-looking statements in the company's quarterly report on Form 10-Q, which was filed today with the SEC and the Risk Factors section of the company's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
